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Abstract Inactivation of peroxisome proliferator-activated
receptor (PPARs) isoforms α, β/δ, and γ mediate distinct
facets of hypertrophic transformation of adult cardiac
myocytes. PPARs are ligand-activated transcription factors
that modulate the transcriptional regulation of fatty acid
metabolism and the hypertrophic response in neonatal
cardiac myocytes. The purpose of this study was to
determine the role of PPAR isoforms in the morphologic
and metabolic phenotype transformation of adult cardiac
myocytes in culture, which, in medium containing 20% fetal
calf serum, undergo hypertrophy-like cell growth associated
with downregulation of regulatory proteins of fatty acid
metabolism. Expression and DNA-binding activity of
PPARα, PPARβ/δ, and PPARγ rapidly decreased after cell
isolation and remained persistently reduced during the 14-day
culture period. Cells progressively increased in size and
developed both re-expression of atrial natriuretic factor and
downregulation of regulatory proteins of fatty acid metabo-
lism. Supplementation of the medium with fatty acid (oleate
0.25 mM/palmitate 0.25 mM) prevented inactivation of
PPARs and downregulation of metabolic genes. Furthermore,
cell size and markers of hypertrophy were markedly reduced.
Selective activation of either PPARα or PPARβ/δ completely
restored expression of regulatory genes of fatty acid metab-
olism but did not influence cardiac myocyte size and markers
of hypertrophy. Conversely, activation of PPARγ prevented
cardiomyocyte hypertrophy but had no effect on fatty acid
metabolism. The results indicate that PPAR activity markedly
influences hypertrophic transformation of adult rat cardiac
myocytes. Inactivation of PPARα and PPARβ/δ accounts for
downregulation of the fatty acid oxidation pathway, whereas
inactivation of PPARγ enables development of hypertrophy.
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Introduction
Phenotypic modification of cardiac myocytes plays a critical
role during the development of myocardial hypertrophy and
progression to heart failure [25]. A number of observations
suggest that morphological and functional changes of
cardiac myocytes are associated with modification of
transcriptional regulation of substrate metabolism including
altered expression of glucose transporter isoforms [32, 36]
and downregulation of genes encoding regulatory proteins
of fatty acid oxidation [26, 27, 39]. To date, very little is
known on the mechanisms linking alterations of the
morphologic and metabolic phenotype.
Peroxisome proliferator-activated receptors (PPARs) are
nuclear receptor transcription factors that are activated by
fatty acid derivatives and, therefore, may modify the
cellular phenotype in response to alteration of cytoplasmic
fatty acid concentration [16, 44]. PPARs bind to the DNA
consensus response element as obligate heterodimers with
retinoid X receptor (RXR) [16]. All three presently known
isoforms, PPARα, PPARβ/δ, and PPARγ, are expressed in
cardiac myocytes [14, 16]. PPARα and PPARβ/δ play a
central role in the transcriptional regulation of fatty acid
oxidation [14]. In fact, PPARα-deficient mice [46] and
mice with cardiac-myocyte-restricted deletion of PPARβ/δ
in the heart [5] exhibit marked reduction of fatty acid
oxidation enzymes in the myocardium and a corresponding
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decrease of fatty acid oxidation. Observations in animal
models have implicated inactivation of PPARα signaling in
the downregulation of fatty acid oxidation enzymes during
overload-induced myocardial hypertrophy and heart failure
[2, 19, 48]. In adipocytes, PPARγ is involved in the
expression of enzymes of synthesis of fatty acids and tri-
glycerides [16], but its role in cardiac myocytes is still poorly
defined.
Studies in neonatal rat cardiac myocytes suggest that
PPAR signaling not only influences regulation of fatty acid
metabolism but also may modify the hypertrophic response.
Selective activation of either PPARα [17, 21], PPARβ/δ
[30], or PPARγ [47] reduced protein synthesis in neonatal
cardiac myocytes exposed to phenylephrine [30, 47],
angiotensin II [47], endothelin-1 [17, 21], or mechanical
strain [47]. Cell size and expression of atrial natriuretic
factor was reduced concomitantly [1, 21, 47]. These
observations are compatible with the hypothesis that
inactivation of PPARα, and possibly of other PPAR
isoforms, may not only mediate downregulation of the
fatty acid oxidation pathway, but also contribute to cardiac
myocyte hypertrophy and dedifferentiation during maladap-
tive remodeling. However, the role of individual PPAR
isoforms in the modification of the morphologic and
metabolic phenotype has not been studied in adult cardiac
myocytes.
In the present study, we investigated the role of PPAR
expression and activity in the phenotypic modification of
adult rat cardiac myocytes (ARC) in long-term culture.
ARC cultured in medium containing 20% fetal calf serum
(FCS) undergo phenotypic transformation that exhibits
similarities to that observed during the development of
maladaptive hypertrophy and heart failure in vivo [41]. The
changes include cellular spreading, re-expression of “im-
mature” isoforms of contractile proteins, and re-expression
of so-called fetal genes [9, 12, 22]. We have previously
observed that the phenotypic modification of ARC is
associated with the return to a fetal-like expression pattern
of metabolic genes. There occurs a shift from glucose
transporter-4 (GLUT4) to glucose transporter-1 (GLUT1)
[23, 35], and downregulation of messenger RNA (mRNA)
expression of a number of regulatory genes of fatty acid
oxidation [37]. We hypothesized that hypertrophy-like
phenotype transformation and downregulation of the fatty
acid oxidation pathway is associated with inactivation of
PPAR signaling.
Materials and methods
The investigation conforms to the Guide for the Care and
Use of Laboratory Animals published by the US National
Institutes of Health (NIH publications no. 85–23, revised
1996) and was approved by the local animal protection
authorities.
Cell isolation and culture
ARC were isolated from male oncins France strain A (OFA)
rats (Charles River, France) weighing 110–120 g by
retrograde perfusion of the hearts with collagenase (Wor-
thington Biochemical) as described previously [13, 23].
After preplating in uncoated dishes (2 h; 37°C) to remove
non-myocyte cells, cardiac myocytes were plated onto
dishes coated with 0.1% gelatin. The culture medium was
M199 supplemented with 20% (vol/vol) FCS (Invitrogen),
1% penicillin/streptomycin, and 20 mmol/l creatine through-
out the culture period. To avoid proliferation of residual
non-myocyte cells, 10 μmol/l 1-β-D-arabinofuranosyl-
cytosine was added to the culture medium. More than 90%
of the cells were myocytes upon visual inspection at light
microscopy after each culture interval with increasing purity
over time. The standard culture medium contained glucose
(5.5 mmol/l). In selected experiments, palmitate and oleate
at equimolar concentration (0.25 mmol/l each, unless
otherwise stated) were added to the culture medium
throughout the entire culture period. Fatty acids were
prebound to serum albumin (0.2 mmol/l) as described
previously [8]. Unlike palmitate alone, palmitate plus oleate
does not elicit apoptosis in ARC [11]. PPAR isoforms were
selectively activated with the PPARα ligand WY-14643
(100 nmol/l; Biomol), the PPARβ/δ ligand L 165–
041 (1 μmol/l; Fluka), or the PPARγ ligand ciglitazone
(10 nmol/l; Biomol). PPAR agonists were dissolved in
dimethyl sulphoxide (DMSO), which was also added
(0.1% vol/vol) to the control cells.
Immunofluorescence and cell surface area determination
ARC were fixed with 4% paraformaldehyde in phosphate-
buffered saline (PBS) and permeabilized with 0.3%
Triton ×−100 in PBS. Primary antibody against sarcomeric
α-actinin (Sigma) was recognized by an anti-mouse
IgG-FITC-conjugated antibody (Sigma). Counterstaining
for F-actin was obtained with rhodamine–phalloidin (Mo-
lecular Probes, Eugene) and DNA staining with 4′,6-
diamidino-2-phenylindole (DAPI; Molecular Probes).
Slides were mounted with VectaShield (Vector Laboratories)
and examined using a Carl Zeiss Axiophot microscope
equipped with an Axiocam color charge-coupled device
(CCD) camera (Carl Zeiss). Images were acquired with the
AxioVision software (Carl Zeiss) and processed with Photo-
shop 3.0.5 (Adobe Systems).
Relative cell surface area was calculated from digitized
cardiac myocyte images taken from random fields of view
using NIH Image software (version 1.62). At least 100 cells
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were measured for each condition by an observer blinded to
the culture conditions.
Protein extraction and western blot
Cells were homogenized in lysis buffer containing Tris–HCl
10 mmol/l, NaCl 150 mmol/l, and ethylenediaminetetraacetic
acid (EDTA) 1 mmol/l, Igepal 1%, sodium deoxycholate
0.5%, sodium dodecyl sulfate (SDS) 0.1%, and protease
inhibitor cocktail (Roche). Proteins (100 μg) were loaded
onto 8.5% SDS polyacrylamide gel electrophoresis (SDS–
PAGE) gels. Ponceau’s red staining was performed to verify
equal loading. Western blot analysis was performed using
polyclonal antibodies against PPARα and PPARγ (Santa
Cruz Biotechnology), PPAR β/δ (Cayman chemicals), fatty
acid translocase (FAT/CD36; Santa Cruz Biotechnology),
medium-chain acyl-CoA dehydrogenase (MCAD; Cayman
Chemicals), and muscle-type carnitine palmitoyltransferase-I
(mCPT-I; a gift from Dr. Gebre Woldegiorgis). Antibodies
were diluted in Tris-buffered saline containing 0.1% Tween
20. All antibodies identified the proper protein band. Specific
signals were detected by chemiluminescence (ECL,
Amersham) and quantified by laser densitometry (Imagequant
3.3, Molecular Dynamics).
DNA-binding activity of PPAR
DNA-binding activities of PPARα and PPARγ were mea-
sured in nuclear extracts prepared as described previously [23]
using an enzyme-linked immunosorbent assay (ELISA)
assay (Active Motif). Briefly, active PPARs in nuclear
extracts bind specifically to consensus oligonucleotides
coated on a well plate and are detected using an antibody
directed against PPAR. Addition of a secondary antibody
conjugated to horseradish peroxidase provides a sensitive
colorimetric readout that is quantified by spectrophotometry.
RNA extraction and quantitative reverse
transcription-polymerase chain reaction
Total RNA was purified using Trizol reagent. After DNAse
(Invitrogen) treatment, RNA was analyzed by reverse
transcription (Superscript II, Invitrogen) followed by real-
time quantitative polymerase chain reaction (PCR; TaqMan,
BioRad). The rat nucleotide sequences of probes, as well as
of forward and reverse primers, were designed from
unconserved sequences of the genes, allowing isoform
specificity (Table 1). The transcripts of the constitutive
housekeeping gene product cyclophilin were quantitatively
measured in each sample, and PCR data were reported as the
number of transcripts per cyclophilin transcript. Cycle number
for cyclophilin was virtually identical in ARC cultured for
14 days (27.5±2.0 cycles/μgRNA) and in freshly isolated
ARC (27.5±1.8 cycles/μg RNA), indirectly suggesting
expression stability over time. Furthermore, identical results
to normalization by cyclophilin were obtained using 18S
ribosomal RNA (rRNA) as housekeeping gene.
Palmitate oxidation
Palmitate oxidation was estimated based on the release of
14CO2 from [1-
14C]-palmitate (Amersham). For measurement
of palmitate oxidation, cells were incubated for 60 min in
sealed flasks containing a suspended filter paper soaked with
an organic base (NCS-II, Amersham) and medium containing
palmitate (0.05 mmol/l), oleate (0.05 mmol/l), and 1 μCi/ml
[1-14C]-palmitate. All fatty acids were complexed to bovine
serum albumin (0.2 mmol/l). The reaction was stopped by
addition of 2N perchloric acid. 14CO2 produced by [1-
14C]-
palmitate metabolism was collected overnight on the filter
paper and quantified by scintillation counting.
Table 1 Primers of RT-PCR assays. F: forward primer, R: reverse
primer, P: probe
Genes Primers and probe sequences
Cyclophilin F 5′-CTG ATG GCG AGC CCT TG-3′
R 5′-TCT GCT GTC TTT GGA ACT TTG TC-3′
P 5′-CGC GTC TGC TTC GAG CTG TTT GCA-3′
ANF F 5′-AGT GCG GTG TCC AAC ACA G-3′
R 5′-CTT CAT CGG TCT GCT CGC T-3′
P 5′-TCT GAT GGA TTT CAA GAA CCT GCT
AGA CCA-3′
BNP F 5′-AAG TCC TAG CCA GTC TCC A-3′
R 5GTC TCT GAG CCA TTT CCT C-3′
P 5′-GCA GAA GCT GCT GGA GCT GAT AA-3′
PPARα F 5′-ACT ACG GAG TTC ACG CAT GTG-3′
R 5′-TTG TCG TAC ACC AGC TTC AGC-3′
P 5′-AGG CTG TAA GGG CTT CTT TCG
GCG-3′
PPARβ/δ F 5′-TGG ATA CGC TTC ACA GTC C-3′
R 5′-GCA GGC TCT AGA ATT CCA TC-3′
P 5′-ACC TGC GGC AGC TGG TCA CTG A-3′
PPARγ F 5′-CCA TTC TGG CCC ACC AAC-3′
R 5′-AAT GCG AGT GGT CTT CCA TCA-3′
P 5′-TCG GAA TCA GCT CTG TGG ACC TCT
CC-3′
FAT/CD36 F 5′-TCC AGC CAA TGC CTT TGC-3′
R 5′-TGG AGATTA CTT TTC AGT GCA GAA-3′
P 5′-TCA CCC CTC CAG AAT CCA GAC AAC
CA-3′
MCAD F 5′-TGG CAT ATG GGT GTA CAG GG-3′
R 5′-CCA AAT ACT TCT TCT TCT GTT GAT
CA-3′
P 5′-AGG CAT TTG CCC CAA AGA ATT TGC
TTC-3′
mCPT-I F 5′-ATC ATG TAT CGC CGC AAA CT-3′
R 5′-ATC TGG TAG GAG CAC ATGG GT-3′
P 5′-TCA AGC CGG TAA TGG CAC TGG G-3′
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[3H]-Phenylalanine incorporation
To obtain an index for the rate of de novo protein synthesis,
ARC were incubated after selected culture intervals for 2 h
at 37°C in serum-free M199 containing 2 μCi/ml of L-
[2,3,4,5-3H]phenylalanine (Amersham) with or without
PPAR agonists. At the end of the incubation period, the
culture medium was removed, and cardiac myocytes were
rinsed three times with ice-cold PBS. DNA and protein
were precipitated by trichloroacetic acid and transferred
into 0.3-M sodium hydroxide. [3H]-Phenylalanine incorpo-
ration and DNA content were determined as reported
previously [34]. [3H]-phenylalanine incorporation was
normalized to nanograms of DNA per sample. Results are
expressed as percentage of the mean value measured in
freshly isolated ARC cultured for measurement of [3H]-
phenylalanine incorporation in standard medium.
Statistics
Results are obtained from at least three independent
experiments and expressed as mean±SEM. Mean group
values were compared by analysis of variance (ANOVA;
Prism 4), applying Bonferroni’s adjustment for multiple
comparisons. P values<0.05 were considered significant.
Results
Fatty acid supplementation of culture medium prevents
ARC hypertrophy and downregulation of mRNA expres-
sion of regulatory proteins of fatty acid metabolism
ARC cultured in medium containing 20% FCS underwent
morphological remodeling as described previously [12, 23].
After 3–4 days of culture, cells resumed spontaneous beating
Fig. 1 Effect of supplementation of the culture medium with fatty
acid (oleate 0.25 mmol/l/palmitate 0.25 mmol/l) on cardiac myocyte
size and ANF expression. a Freshly isolated cardiac myocyte. After
14 days of culture in medium containing 20% FCS, cardiac myocytes
had increased in size and assumed a polymorphic shape (b and c).
Cells cultured in fatty-acid-free medium were larger (b) than in
medium containing oleate/palmitate (c). Green α-Actinin, blue
nucleus, and red phalloidine. d Relative difference of cell size
estimated by planimetry on days 7 and 14 (control, open bars; fatty
acid, filled bars; at least 100 cells in three to six different cultures were
measured for each condition). e and f Change in ANF and BNP
mRNA expression relative to freshly isolated cardiac myocytes (n=6
for each condition). ANF (e) and BNP (f) expression were markedly
lower in cells cultured during 14 days with fatty acids (filled squares)
compared with those cultured without fatty acids (open squares). g De
novo protein synthesis, estimated from [3H]-phenylalanine incorpora-
tion (n, at least four independent experiments), increased throughout
the culture period (open squares) and was attenuated by fatty acids
(filled squares). Values are means+SEM. *P<0.05 compared with
“without fatty acid.” **P<0.05 between indicated groups
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and continuously increased in size throughout the 14-day
culture period (Fig. 1a–d). The rate of de novo protein
synthesis, estimated from [3H]-phenylalanine incorporation,
also continuously increased (Fig. 1g). Moreover, mRNA
expression of atrial natriuretic factor (ANF) increased
progressively and averaged, after 14 days, 409±25% of the
value measured in freshly isolated cardiac myocytes
(Fig. 1e). Similarly, brain natriuretic peptide (BNP) mRNA
increased to 225±9% (P<0.05; Fig. 1f). Supplementation of
the culture medium with 0.5 mmol/l fatty acids (palmitate
0.25 mmol/l plus oleate 0.25 mmol/l) during the entire
culture period reduced cell spreading with a decrease of cell
surface area by 29 and 33% after 7 and 14 days, respectively,
compared with cells cultured in standard medium (Fig. 1b–d).
The rate of de novo protein synthesis leveled off after 5 days
in the presence of fatty acids and remained constant thereafter
(Fig. 1g). Fatty acids markedly attenuated the increase of
ANF mRNA (Fig. 1e) and prevented the increase of BNP
mRNA, which averaged, after 14 days, 107±14% of the
values measured in freshly isolated cardiac myocytes
(Fig. 1f). No appreciable effect of fatty acids on contractile
function was observed.
We monitored the expression of three PPAR target genes
that are involved in the regulation of fatty acid metabolism:
fatty acid translocase (FAT/CD36), medium-chain acyl-
CoA dehydrogenase (MCAD), and muscle-type carnitine
palmitoyltransferase-I (mCPT-I). In standard medium, mRNA
expression of MCAD, FAT/CD36, and mCPT-I decreased
rapidly after cell isolation to 50 to 70% of values measured in
freshly isolated cardiac myocytes and continued to decrease
thereafter to 15 to 35% after 14 days (Fig. 2a–c). Interestingly,
there was no concomitant decrease of protein expression of
Fig. 2 Effect of supplementation of the culture medium with fatty
acids on mRNA expression of regulatory proteins of fatty acid
metabolism. mRNA expression of FAT/CD36 (a), mCPT-I (b), and
MCAD (c) decreased rapidly after isolation and remained low in
cardiac myocytes cultured without fatty acid (open squares). The
reduction compared with freshly isolated cardiac myocytes was
significant for each culture period (P<0.05). In the presence of
0.5 mmol/l fatty acids (oleate 0.25 mmol/l plus palmitate 0.25 mmol/l;
filled squares), mRNA expression of all three proteins steadily
increased to supranormal values (n, at least five determinations for
each data point). d Effect of increasing fatty acid (FA) concentration
on mRNA expression of FAT/CD36 (circles), mCPT-I (squares), and
MCAD (triangles). Stimulation of mRNA expression was observed at
all examined total fatty acid concentrations>0.1 mmol/l. Each fatty
acid concentration consisted of equimolar proportions of oleate and
palmitate. Values are means±SEM. *P<0.05 compared with “without
fatty acid”
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MCAD, FAT/CD36, and mCPT-I after 14 days (Fig. 3a).
Likewise, oxidation of palmitate was only slightly reduced
by 21% compared with freshly isolated ARC (Fig. 3b).
Supplementation of the medium with fatty acid did not
prevent the initial drop of mRNA expression of MCAD, FAT/
CD36, and mCPT-I (Fig. 2a–c). However, mRNA expression
increased steadily thereafter. Stimulation of mRNA expres-
sion was observed at total fatty acid concentrations higher
than 0.1 mmol/l (Fig. 2d). In the presence of a total fatty acid
concentration of 0.5 mmol/l, values measured after 14 days
were equal (FAT/CD36) or higher (mCPT-I, MCAD) than
those measured in freshly isolated cardiac myocytes
(Fig. 2a–c). Concomitantly, protein expression of MCAD,
FAT/CD36, and mCPT-I was increased roughly by 50%
compared with values measured in ARC cultured without
fatty acid (Fig. 3a), and oxidation of palmitate was
approximately doubled (Fig. 3b).
Reduction of transcriptional activity of PPARα, PPARβ/δ,
and PPARγ in ARC is restored by fatty acid
supplementation
We determined whether the expression and/or DNA-
binding activity of PPARs are altered in ARC undergoing
phenotypic changes. In ARC cultured in standard medium,
mRNA expression levels of PPARα, PPARβ/δ, and PPARγ
were decreased to less than 50% of the values measured in
freshly isolated ARC throughout the entire 14-day culture
interval (Fig. 4a). However, protein expression decreased
only transiently (day 1) and was restored by day 3 to values
comparable to those measured in freshly isolated ARC,
without further change up to day 14 (Fig. 4b). DNA-
binding activity of PPARα and PPARγ (binding activity of
PPARβ/δ was not measured) decreased to approximately
50% of values measured in freshly isolated ARC and, in
contrast to protein expression, did not appreciably recover
thereafter (Fig. 4c and d). Thus, cardiac myocyte remodel-
ing seems to be associated with reduced DNA binding,
rather than reduced protein expression of PPAR isoforms.
Supplementation of the culture medium with fatty acids
largely restoredDNA binding of PPARα and PPARγ by day 7
(Fig. 4c and d). mRNA expression of all PPAR isoforms was
also restored by fatty acid, showing a similar time course
(only data for day 14 displayed; Fig. 4a). This presumably
reflects the known presence of PPAR response elements
(PPRE) in the promoter region of PPAR genes [30].
Differential effects of PPAR isoforms on metabolic
and morphologic phenotype of ARC
To determine the role of individual PPAR isoforms, ARC
were treated with specific agonists of either PPARα (WY-
14643), PPARβ/δ (L 165-041), or PPARγ (ciglitazone). As
each PPAR isoform transactivates its own expression,
specificity of compounds was validated by measurement of
the effect on PPAR mRNA expression in standard medium.
At the selected concentration, each agonist selectively
restored mRNA expression of the corresponding PPAR
isoform to values comparable to those measured in freshly
isolated cells (Fig. 5a). DNA-binding activity was measured
for PPARα and PPARγ. WY-14643 and ciglitazone selec-
tively increased DNA-binding activity of PPARα and
PPARγ, respectively (Fig. 5b). Thus, the selected agonists
selectively activated PPAR isoforms in ARC.
The effect of selective activation of each PPAR isoform on
the expression of regulatory genes of fatty acid metabolism
Fig. 3 Effect of supplementation of the culture medium with fatty
acids (oleate 0.25 mmol/l plus palmitate 0.25 mmol/l) on protein
expression of regulatory proteins of fatty acid oxidation (a) and
palmitate oxidation (b). a On day 14, protein expression of FAT/
CD36, mCPT-I, and MCAD was approximately 50% higher in ARC
cultured with fatty acids (filled bars) compared to ARC cultured
without fatty acids (open bars; n, at least six determinations for each
data point). b Palmitate oxidation in cardiac myocytes immediately
after isolation (freshly isolated ARC, n=6) and in cells cultured for
14 days without (open bar, n=5) and with fatty acids (filled bar, n=4).
Palmitate oxidation was higher in the presence of fatty acids. Values
are means±SEM. *P<0.05 compared with “without fatty acid”. **P<
0.05 between indicated groups
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and hypertrophic markers is shown in Figs. 6 and 7. Activation
of PPARα or PPARβ/δ by WY-14643 or L 165–041,
respectively, restored mRNA expression of FAT/CD36,
mCPT-I, and MCAD to values comparable to those measured
in freshly isolated cardiac myocytes (Fig. 6a–c). Conversely,
activation of PPARγ by ciglitazone had no effect on the
expression of genes of fatty acid metabolism (Fig. 6a–c).
Cell surface area of ARC cultured for 14 days in
standard medium was significantly reduced by ciglitazone
by 37% compared with the control (Fig. 7a). Ciglitazone
also decreased the rate of de novo protein synthesis by 22%
(Fig. 7c). Furthermore, ciglitazone reduced expression of
ANF by 53% (Fig. 7b) and of BNP by 31% (P<0.05). In
contrast, WY-14643 and L 165–041 did not alter cell
surface area, protein synthesis, expression of ANF, or
expression of BNP (Fig. 7a–c).
Discussion
Ventricular myocytes of adult rat hearts cultured in medium
containing 20% FCS undergo a progressive remodeling
process. Phenotypic changes include an increase in cell
size, acceleration of de novo protein synthesis and re-
expression of so-called “fetal genes,” resembling cardiac
myocyte hypertrophy in vivo [9, 12, 23, 41]. ARC,
therefore, offer a homogenous system for delineating the
effects of individual stimuli on the hypertrophic response in
terms of gene expression and cell morphology. The present
study implicates all three PPAR isoforms expressed in the
myocardium in an isoform-specific manner as modulators
of the morphologic and metabolic phenotype of adult
cardiac myocytes. The results demonstrate in ARC in
long-term culture that: (1) the progressive hypertrophic
response and the downregulation of genes controlling fatty
acid oxidation are associated with inactivation of PPARα,
PPARβ/δ, and PPARγ at unaltered protein levels; (2)
PPAR-inactivation is reversed, and both metabolic and
hypertrophic changes are attenuated, by supplementation of
the culture medium with fatty acid; and (3) in fatty-acid-
free medium, selective activation of PPARα or PPARβ/δ,
but not of PPARγ, restores expression of regulatory proteins
of fatty acid metabolism, without a change of markers of
hypertrophy. Conversely, activation of PPARγ attenuates
Fig. 4 Changes of expression and DNA-binding activity of PPAR
isoforms. In cardiac myocytes cultured in standard medium. mRNA
expression by RT-PCR of PPARα, PPARβ/δ, and PPARγ (a) was
reduced by at least 50% during the entire culture period. In the
presence of fatty acids, mRNA expression was not reduced after
14 days. Protein expression (b) dropped only transiently, immediately
after isolation, and completely recovered thereafter. DNA-binding
activity (measured by ELISA) of PPARα (c) and PPARγ (d)
decreased immediately after isolation and remained low in standard
medium (open squares). Fatty acid supplementation largely restored
DNA-binding activity (filled squares). Values are means±SEM of at
least three determinations for each data point. *P<0.05 compared with
freshly isolated ARC
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markers of hypertrophy, without influencing expression of
genes of fatty acid metabolism.
Similar to previous observations by others in neonatal
cardiac myocytes, we have found that all three isoforms,
PPARα, PPARβ/δ, and PPARγ, are expressed in adult rat
cardiac myocytes. mRNA expression of each isoform rapidly
decreased in ARC cultured in standard medium and remained
low throughout the 14-day culture period. Conversely, protein
Fig. 6 Effect of activation of
PPARα, PPARβ/δ, and PPARγ
by WY-14643, L-165–041, and
ciglitazone, respectively, on
mRNA expression of FAT/CD36
(a), mCPT-I (b), and MCAD (c).
Specific ligands of PPARα and
PPARβ/δ (WY-14643, L 165–
041) restored expression of each
regulatory protein of fatty acid
oxidation. Activation of PPARγ
by ciglitazone had no effect.
Values are means±SEM of at
least four determinations. *P<
0.05 compared with untreated
cells (control)
Fig. 5 Effect of specific activation of PPAR isoforms on mRNA
expression (a) and DNA-binding activity (b) after 14 days of culture.
a Activation of PPARα by WY-14643 (100 nmol/l), of PPARβ/δ by L
165–041 (1 μmol/l), and of PPARγ by ciglitazone (10 nmol/l) restored
mRNA expression of the corresponding PPAR isoform. b DNA
binding of PPARα was increased by WY-14643 and that of PPARγ by
ciglitazone. Values are means±SEM of at least five determinations.
*P<0.05 compared with untreated cells (control)
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expression decreased only transiently and returned to levels
measured immediately after isolation within 3 days, suggest-
ing posttranscriptional compensation by as yet unknown
mechanisms. However, DNA-binding activity of PPARα
and PPARγ was reduced by roughly 50% during the entire
culture period, compared with freshly isolated cells (binding
activity of PPARβ/δ not measured). mRNA expression and
DNA-binding activity exhibited a similar time-course most
likely reflecting the fact that PPARs transactivate their own
expression [3]. This is further supported by the observation
that specific activation of PPARα and PPARγ by WY-14643
and ciglitazone, respectively, restored both DNA-binding
activity and mRNA expression of the corresponding isoform.
Although not measured, we anticipate that PPARβ/δ was also
inactivated because mRNA expression was reduced and could
be reactivated by L 165–041. Collectively, the results provide
circumstantial evidence that transcriptional activity of all three
PPAR isoforms is reduced in ARC undergoing phenotype
transformation, despite unaltered protein expression.
There is evidence that PPAR signaling is altered during
the development of maladaptive myocardial hypertrophy in
vivo. Reduction of both myocardial expression and activity
of PPARα has been observed in rodents with mechanical
overload induced by constriction of either the aorta [2, 48]
or the pulmonary artery [38]. Mechanisms that may
contribute to the inactivation of PPARα during cardiac
hypertrophy include phosphorylation of PPARα by extra-
cellular signal-regulated MAP kinase [2], increased expres-
sion of the competing repressor chicken ovalbumin
upstream promoter-transcription factor (COUP-TF) [38],
or reduced availability of the co-activator PGC-1α [2, 20].
mRNA expression of FAT/CD36, CPT-I, and MCAD,
which are target genes of PPARα and PPARβ/δ, decreased
in ARC concomitantly with the reduction of DNA-binding
activity (and mRNA expression) of PPARs. An interesting
finding was that both protein expression and palmitate
oxidation were not reduced concomitantly but, similar to
PPARs protein expression, was maintained at levels compa-
rable to those measured in freshly isolated cardiac myocytes.
A dissociation between mRNA and protein expression of
genes of fatty acid oxidation has also been observed in
hypertrophic myocardium of spontaneously hypertensive rats
[39] and of mice with targeted overexpression of angiotensi-
nogen in the myocardium [27]. In these rodent models of
progressive hypertrophy, in vivo protein expression and
enzyme activity of MCAD was maintained at control level
during compensated hypertrophy, despite marked reduction
of mRNA, but dropped markedly after the onset of heart
failure [27, 39]. Taken together, these observations suggest
the involvement of posttranscriptional mechanisms in the
control of levels of regulatory proteins of fatty acid
metabolism during cardiac myocyte remodeling. However,
the underlying molecular events are presently not known.
Inclusion of fatty acids (oleate 0.25 mmol/l plus palmitate
0.25 mmol/l) in the culture medium restored mRNA expres-
sion of PPARα, PPARβ/δ, and PPARγ, and DNA-binding
activity. Both mRNA and protein expression of FAT/CD36,
mCPT-I, and MCAD increased to levels exceeding those
measured in freshly isolated ARC. Concomitantly, fatty acid
oxidation rate was higher than in freshly isolated cells.
Analogous findings have been reported for neonatal rat
cardiac myocytes [14, 45]. However, in contrast to observa-
tions in neonatal cardiac myocytes cultured for 48 h [45],
exposure to fatty acid not only increased the expression of
the fatty acid oxidation pathway, but also attenuated cardiac
myocyte growth, protein synthesis, and expression of
hypertrophy marker genes. After 14 days of culture, adult
rat cardiac myocytes were smaller by 33%, and both ANF
and BNP mRNAs were reduced by more than 50%. The
results are compatible with the hypothesis that inactivation of
PPAR signaling contributes to morphologic and metabolic
remodeling of cardiac myocytes.
Fig. 7 Effect of activation of PPAR isoforms by specific ligands on
cell surface (a), ANF mRNA expression (b), and de novo protein
synthesis (c). Activation of PPARα by WY-14643 and PPARβ/δ by L
165–041 had no effect. Activation of PPARγ by ciglitazone decreased
cell surface, ANF expression, and de novo protein synthesis to a
comparable extent as fatty acid. Values are means±SEM of at least
four determinations. *P<0.05 compared with untreated cells (control)
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The contribution of individual PPAR isoforms to pheno-
type modification of ARC has been determined in experi-
ments using specific agonists. The results indicate that PPAR
isoforms have distinct effects. Consistent with previous
studies in neonatal cardiac myocytes in short-term culture
[14], activation of PPARα or PPARβ/δ by WY-14643 and L
165-041, respectively, restored expression of regulatory
genes of fatty acid metabolism. Conversely, activation of
PPARγ by ciglitazone, as previously observed in neonatal
cardiac myocytes [14], had no effect on metabolic genes.
In the present study, activation of PPARα and PPARβ/δ
had no effect on cardiac myocyte size, protein synthesis, and
the expression of ANF and BNP. This is in apparent contrast
to previous observations in neonatal cardiac myocytes. In fact,
activation of PPARα reduced the hypertrophic response in
neonatal rat cardiac myocytes exposed to endothelin-1 [17,
21]. A similar effect has been observed after activation of
PPARβ/δ by L 165–041 in phenylephrine-stimulated neona-
tal rat cardiac myocytes [30]. The reason for the absence of
an antihypertrophic effect of activation of PPARα and
PPARβ/δ in ARC is not apparent from the available data.
However, at least three major differences in the experimental
conditions should be considered: First, ARC and neonatal
cardiac myocytes exhibit differences in the signaling path-
ways involved in hypertrophy [42]. Second, in neonatal
cardiac myocytes, antihypertrophic effects of PPAR activa-
tion have been studied during stimulation by endothelin-1 or
phenylephrine [17, 21, 30]. Third, studies in neonatal cardiac
myocytes were limited to 1 to 3 days [30, 43, 47], whereas in
the present study ARC were followed for 14 days.
In contrast to activation of PPARα and PPARβ/δ,
activation of PPARγ by ciglitazone markedly reduced cardiac
myocyte growth and protein synthesis in ARC, and decreased
mRNA expression of ANF and BNP. Antihypertrophic effects
of PPARγ signaling have also been observed in neonatal
cardiac myocytes stimulated by angiotensin II [1, 47],
phenylephrine [47], or mechanical strain [47]. Preliminary
observations from our laboratory indicate that reactivation of
PPARγ also attenuates angiotensin-II-mediated hypertrophy
of ARC [28]. Interestingly, mice with targeted knockout of
PPARγ in the myocardium develop ventricular hypertrophy
even without exogenous hypertrophic stimulus, suggesting
that PPARγ may suppress the hypertrophic gene program
even in unstressed conditions [10]. Moreover, the hypertro-
phic response to pressure overload is enhanced in mice with
cardiac-myocyte-restricted PPARγ deletion [10]. Conversely,
PPARγ agonists inhibit ventricular hypertrophy induced by
aortic constriction in wild-type mice [1, 40].
Whereas upregulation of genes of fatty acid metabolism
most likely is mediated by direct interaction of the PPAR/
RXR heterodimer with the promoter region [4, 6], the
molecular mechanisms of attenuation of the hypertrophic
response is less clear. DNA-binding-independent inactivation
of other transcription factors (transrepression) may be
involved in the antihypertrophic effects [7, 18, 29]. Studies
in neonatal cardiac myocytes exposed to hypertrophic stimuli
have demonstrated that activation of PPARγ [43, 47], but
also of PPARα [43] and PPARβ/δ [30], inactivate NF-κB
that is essential for hypertrophy in this model [15, 31].
Observations in macrophages raise the possibility that
PPARγ may antagonize activity of other transcription factors
potentially involved in hypertrophy, including activator
protein-1 (AP-1) and STAT [33].
Collectively, this study demonstrates that PPAR activity
considerably modulates phenotypic transformation of adult
rat cardiac myocytes in culture. PPARα and PPARβ/δ on
one hand, and PPARγ on the other hand, differ not only in
their effects on the expression of regulatory proteins of fatty
acid metabolism, but also in their modification of the
hypertrophic response. This observation may be relevant
for the development of therapeutic strategies designed to
modify myocardial remodeling because restoration of fatty
acid metabolism and attenuation of the hypertrophic
response may differentially affect the remodeling process
[24, 48].
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